Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.
Stocks · News reference
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.